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Inactivated and fowlpox virus (FP)-vectored vaccines have been used to control H5 avian influenza (AI) in
poultry. In H5 AI endemic countries, breeder flocks are vaccinated and therefore, maternally-derived antibodies
(MDA) are transferred to their progeny. Results of three immunogenicity and one efficacy studies performed
in birds with or without MDA indicated that the immunogenicity of an inactivated vaccine based on a H5N9
AI isolate (inH5N9) was severely impaired in chicks hatched from inH5N9-vaccinated breeders. This MDA
interference was lower when breeders received only one administration of the same vaccine and could be
overcome by priming the chicks at day-of-age with a live recombinant FP-vectored vaccine with H5 avian
influenza gene insert (FP-AI). The interference of anti-FP MDA was of lower intensity than the interference of
anti-AI MDA. The highest interference observed on the prime-boost immunogenicity was in chicks hatched
from breeders vaccinated with the same prime-boost scheme. The level of protection against an antigenic
variant H5N1 highly pathogenic AI isolate from Indonesia against which the FP-AI or inH5N9 alone was poorly
protective could be circumvented by the prime-boost regimen in birds with either FP or AI MDA. Thus, the
immunogenicity of vaccines in young chicks with MDA depends on the vaccination scheme and the type of
vaccine used in their parent flocks. The heterologous prime-boost in birds with MDA may at least partially
overcome MDA interference on inactivated vaccine.Introduction
Vaccines are useful tools to control avian influenza (AI)
especially when biosecurity and stamping out strategies
alone are not successfully implemented [1-3]. Inactivated
vaccines are the most widely used AI vaccines although
viral vectored vaccines based on fowlpox (FP) or Newcastle
disease virus (NDV) are also used in some countries [4-6].
In endemic countries in which AI vaccination is routinely
used in breeders, broilers hatch with maternally-derived
antibodies (MDA). A few papers reported the negative
effect of MDA on inactivated AI and vector vaccines
immunogenicity and efficacy in chickens [7-12].
A FP-vectored AI (FP-AI) vaccine expressing the
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article, unless otherwise stated.1378/1983 H5N8 highly pathogenic AI (HPAI) isolate
has been used in broilers since 1998 in low pathogenic
avian influenza (LPAI) H5N2 endemic areas of Central
America. One of the main advantages of this FP-AI vac-
cine is that it is administered to one-day-old chicks by
the subcutaneous route at the hatchery whereas inacti-
vated AI vaccines are usually administered in the farms
at a later age. The FP-AI vaccine is also a DIVA (differ-
entiating infected from vaccinated animals) vaccine since it
induces an immune response against the HA alone and
some commercially available enzyme-linked immunosorb-
ent assays (ELISA) are designed to detect the antibody re-
sponse against the nucleoprotein (NP); these ELISAs can
therefore detect infection in a FP-AI vaccinated flock. The
FP-AI efficacy in presence of FP and/or H5 AI virus MDA
has been shown in a highly pathogenic AI (HPAI) as well
as low pathogenic AI (LPAI) Mexican H5N2 challengeCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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be efficacious against different HPAI H5N1 isolates in SPF
chicks [14,15]. The objective of the studies presented here
was to further analyse the effect of MDA on FP-AI vaccine
immunogenicity and to evaluate the efficacy of a prime-
boost regimen (priming with FP-AI and boosting with
inactivated vaccine) in birds with FP or AI MDA.
Material and methods
Vaccines
Three AI vaccines were used: a classical inactivated and
two recombinant FP vectored vaccines. The whole virus
beta-propiolactone (BPL)-inactivated vaccine (inH5N9)
contained the Eurasian isolate A/chicken/Italy/22A/98
[H5N9] (Genbank HA gene: ABR37720), propagated on
embryonated SPF eggs (experimental vaccine prepared
by Merial Italia S.p.A.). The inactivated antigen (H5N9-
It) was formulated in a water-in-oil adjuvant similar to
those used in classical avian inactivated vaccines. Two
different experimental formulations of H5N9-It inacti-
vated vaccine (inH5N9) were used. For studies 1 and 2,
the vaccine was formulated at 0.5 mL (350 HA units)
per dose and for studies 3 and 4, it was formulated
at 0.3 mL (122 HA units) per dose. The first vectored
vaccine contained an experimental FP recombinant
(vFP2211) expressing a synthetic hemagglutinin (HA)
gene derived from the amino acid sequence of the HA
from A/chicken/Indonesia/7/2003 clade 2.1.1 H5N1
HPAI isolate (GenBank: ABO30346) that was modified
at the cleavage site (RERRRKKRGLF mutated into
RETRGLF) [7]. The other FP vectored vaccine was the
TROVAC®-AIV H5 (batches TAH5RF064 (study 2),
RD021 (study 3), and RD030 (study 4) produced by
Merial Select, Inc., Gainesville, Georgia, USA) vaccine li-
censed in the USA and other countries. This vaccine
contains the FP recombinant vFP89, which expresses the
HA gene (Genbank: HMIVT8) of a HPAI H5N8 virus
isolated in Ireland (A/turkey/Ireland/1378/83 [H5N8]).
The FP vector (TROVAC® vector), insertion site and
promoter were the same for the two FP vectored vac-
cines. It was derived from the seed of the commercial FP
vaccine DIFTOSEC CT® (batch 5DCC3511 (breeders of
study 1 and 2) and batch 7DCC3801-A (breeders of
study 3 and 4) produced by Merial S.A.S., Lyon, France)
that was also used as the FP vaccine in our studies.
Experimental design
Study 1 (Immunogenicity study)
Five groups of 10 one-day-old chickens were included in
this study. These birds were hatched either from unvac-
cinated SPF hens or from SPF hens vaccinated twice
with inH5N9 (0.5 mL) at 3 and 17 weeks of age respect-
ively. These hens were also vaccinated with FP vaccine
at 9 weeks of age. Serum was collected from 15 out of19 hens at 36 and 44 weeks of age for AI serology. The
chicks hatched from eggs collected from 42 week-old
vaccinated hens had either no MDA or both anti-FP and
anti-H5N9 maternal antibodies (named hereafter MDA-
FP +H5N9). Chicks without MDA were vaccinated with
vFP2211 at 3 log10 TCID50/dose at day 0 (D0). Chicks
with MDA-FP +H5N9 were vaccinated either with
vFP2211 at 3 log10 TCID50/dose at D0, with vFP2211 at
5 log10 TCID50/dose at D0, with vFP2211 at 5 log10
TCID50/dose at D0 and 0.5 mL of inH5N9 at day 21
(D21) (prime-boost), or with 0.5 mL of inH5N9 at D21
only. The design of this study is shown in Table 1. Vac-
cination was performed subcutaneously in the nape of
the neck at D0 for vFP2211 and intramuscularly in the
breast at D21 for inH5N9. Blood was taken 3 weeks after
the first vaccination and 3 and 9 weeks after the second
vaccination to assess the seroconversion. The level of
MDA was evaluated from the serum of 10 additional
chicks euthanized after hatch.
Study 2 (Immunogenicity study)
Three groups of 10 one-day-old chickens were included
in this study. One group of SPF birds was immunized
with vFP89 at 3 log10 TCID50/dose at D0 and with
0.5 mL of inH5N9 at D21 (prime-boost in SPF chickens
without MDA). The birds of the two other groups were
hatched from SPF hens vaccinated twice with inH5N9
(0.5 mL) at 3 and 17 weeks of age and once with FP vac-
cine at 9 weeks of age; serum was collected from 15 out
of 19 hens at 60 and 68 weeks of age for AI serology.
The chicks from these two other groups were hatched
from eggs collected from 62 week-old vaccinated hens
and had both anti-FP and anti-H5N9 maternal anti-
bodies (MDA FP +H5N9). One of these 2 other groups
was vaccinated with vFP89 at 3 log10 TCID50/dose at D0
and with 0.5 mL of inH5N9 at D21 (prime-boost), and
the other at both D0 and D21 with inH5N9 (0.2 and
0.5 mL respectively) (see Table 1). Vaccination was per-
formed subcutaneously in the nape of the neck at D0 and
intramuscularly in the breast at D21. Blood was taken
3 weeks after the first vaccination and 1 and 3 weeks after
the second vaccination to assess the seroconversion. The
level of transmitted MDA was evaluated from the serum
of 7 additional chicks euthanized after hatch.
Study 3 (Immunogenicity study)
Eight groups of 10 one-day-old chickens were included
in this study. Birds were hatched from 4 different groups
of hens: (1) non-vaccinated SPF, (2) SPF vaccinated 3
times with inH5N9 (0.3 mL) at 3, 6 and 16 weeks of age,
(3) SPF vaccinated twice with FP vaccine at 4 and
12 weeks of age or (4) SPF vaccinated with vFP89 at 3
log10 TCID50/dose at D0, FP vaccine at 12 weeks of age
and with 0.3 mL of inH5N9 at 16 weeks of age. Serum
Table 1 Vaccination schemes of the four studies
Study Chickens 1st vaccination at day 0 2nd vaccination at day 21 (studies 1 and 2)
or at day 14 (studies 3 and 4)
Challenge
Vaccine Dose Vaccine Dose
1 SPF vFP2211 103 TCID50 - - No
H5N9 + FP MDA vFP2211 103 TCID50 - -
vFP2211 105 TCID50 - -
vFP2211 105 TCID50 inH5N9 0.5 mL
- - inH5N9 0.5 mL
2 H5N9 + FP MDA inH5N9 0.2 ml inH5N9 0.5 mL No
vFP89 103 TCID50 inH5N9 0.5 mL
SPF vFP89 103 TCID50 inH5N9 0.5 mL
3 SPF vFP89 103 TCID50 inH5N9 0.3 mL No
- - inH5N9 0.3 mL
H5N9 MDA vFP89 103 TCID50 inH5N9 0.3 mL
- - inH5N9 0.3 mL
FP vFP89 103 TCID50 inH5N9 0.3 mL
- - inH5N9 0.3 mL
H5(N8)* + H5N9 + FP MDA vFP89 103 TCID50 inH5N9 0.3 mL
4 SPF - - - - Yes (D28)
vFP89 103 TCID50 - -
FP MDA vFP89 103 TCID50 inH5N9 0.3 mL
- - inH5N9 0.3 mL
H5N9 MDA - - - -
vFP89 103 TCID50 - -
vFP89 103 TCID50 inH5N9 0.3 mL
- - inH5N9 0.3 mL
Chickens were hatched from unvaccinated (SPF) or vaccinated (MDA) hens. Chicks with H5N9, FP, H5N8 and/or H5N1 MDA were the progeny of hens vaccinated
with inH5N9, fowlpox (FP), vFP89 (HA gene from A/turkey/Ireland/1378/83 [H5N8]) and/or vFP2211 (HA gene from A/chicken/Indonesia/7/2003 [H5N1]),
respectively. The groups of 9 to 10 one-day-old birds received either vFP2211 or vFP89 or inH5N9 at D0, followed by a boost of inH5N9 at D21 (studies 1and 2) or
at D14 (studies 3 and 4). In addition, a HPAI H5N1 challenge was performed in study 4.
*H5(N8) MDA are directed against the HA only of A/turkey/Ireland/1378/83 [H5N8]. Breeders of these chicks were indeed vaccinated with a fowlpox expressing
the HA of H5N8 (vFP89).
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and from 10 out of 20 hens of group (4) at 20 and
28 weeks of age for AI serology. The chicks were
hatched from eggs collected from 24 week-old vac-
cinated hens and had either (1) no MDA, (2) anti-
H5N9, (3) anti-FP or (4) anti-FP, anti-H5(N8) (against
A/turkey/Ireland/1378/83 [H5N8] HA only) and anti-
H5N9 maternal antibodies. These chicks were vacci-
nated with vFP89 at 3 log10 TCID50/dose at D0 and
with 0.3 mL of inH5N9 at day 14 (D14) (prime-boost)
or only once at D14 with 0.3 mL of inH5N9 (see
Table 1). Vaccination was performed subcutaneously in
the nape of the neck at D0 and intramuscularly in the
breast at D14. Blood was taken 2 weeks after the first
vaccination and 2 and 4 weeks after the second vaccin-
ation to assess the seroconversion. The level of MDA
was evaluated from the serum of 5 additional chicks
euthanized after hatch.Study 4 (challenge study)
Eight groups of 9-10 one-day-old chickens were included
in this study. Birds were hatched from 3 different groups
of hens: (1) non-vaccinated SPF, (2) SPF vaccinated twice
with FP vaccine at 4 and 12 weeks of age, (3) SPF vacci-
nated 3 times with inH5N9 at 3, 6 and 16 weeks of age.
Serum was collected from 10 out of 15 hens from group
(3) at 52 and 60 weeks of age for AI serology. The chicks
were hatched from eggs collected from 58 week-old vac-
cinated hens and had either (1) no MDA, (2) anti-FP or
(3) anti-H5N9 maternal antibodies. Chicks without MDA
were vaccinated either with vFP89 at 3 log10 TCID50/dose
at D0 or remained unvaccinated. Chicks with anti-FP
MDA were vaccinated with vFP89 at D0 and with 0.3 mL
of inH5N9 at D14 (prime-boost) or at D14 only with
0.3 mL of inH5N9. Chicks with anti-H5N9 MDA were ei-
ther non-vaccinated, vaccinated with vFP89 at D0, vacci-
nated with 0.3 mL of inH5N9 at D14, or vaccinated with
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boost) (see Table 1). Vaccination was performed sub-
cutaneously in the nape of the neck at D0 (vFP89) and
intramuscularly (inH5N9) in the breast at D14. All birds
were challenged by the intranasal route at day 28 (D28)
with 106 EID50 per bird of the Indonesian A/chicken/
West Java-Subang/29/2007 HPAI H5N1 isolate classi-
fied in 2.1.3.2 subclade [16]. The HA sequence of the
A/chicken/West Java/29/002/2007 isolate available in
GISAID’s EpiFlu™ Database [17] (Accession number
EPI533441) was used for sequence analysis. This isolate
was previously used in a published vaccination-challenge
study [18] and is one of the antigenic variants that emerged
in Indonesia as early as 2005 [16]. Morbidity and mortality
were recorded during 2 weeks after challenge and oropha-
ryngeal swabs were collected 2 and 4 days post-challenge
to evaluate viral load by quantitative real time RT-PCR.
Blood was taken 2 weeks after the first vaccination (D14)
and 2 weeks after the second administration before chal-
lenge (D28). The level of MDA was evaluated from the
serum of 5 additional chicks euthanized after hatch.
Sequence and laboratory analysis
The identity and similarity between the HA1 amino acid
sequence of the vaccine strains, the challenge isolate and
the viruses used as antigens in the HI test (Table 2) were
obtained using the Blastp software of the National Cen-
ter for Biotechnology Information [19].
The serological analyses were performed using the
hemagglutination inhibition (HI) tests. Tests were con-
ducted according to standard procedures, using 4 HA
units/well. Different antigens were tested to check for
cross-reactivity of the serums towards different recent
H5N1 strains. The BPL-inactivated A/chicken/Italy/22A/
98 [H5N9] (homologous to the inactivated vaccine
strain) was tested on serums from all studies. The BPL-
inactivated NIBRG14 H5N1 antigen was used on serums
from studies 1 and 2; the NIBRG14 is a 6/8 PR8-basedTable 2 Amino acid sequence identity (up right) and similarit
strains used for vaccines, challenge and/or HI test antigens
Identity→ tk/Ire/83 H5N8 ck/Ind/03 H5N1 ck/Ita/9
Similarity ↓
tk/Ire/83 H5N8 88.0% 91.4%
ck/Ind/03 H5N1 94.8% 89.3%
ck/Ita/98 H5N9 96.3% 94.5%
Vtn/04 H5N1 95.1% 97.5% 93.9%
tk/Tur/05 H5N1 94.2% 98.2% 93.9%
ck/WJ/07 H5N1 91.1% 94.8% 91.7%
The HA gene of A/turkey/Ireland/1378/83 [H5N8] (tk/Ire/83 H5N8) and of A/chicken
genome of fowlpox recombinant vFP89 and vFP2211, respectively. The A/chicken/It
The NIBRG14 and NIBRG23 reverse genetics constructs contain the HA and NA gen
turkey/Turkey/1/2005 [H5N1 clade 2.2] (tk/Tur/05 H5N1), respectively. The A/chicken
for the challenge in study 4.reverse genetics mutant containing the HA (Genbank:
ACR48874) and NA of the A/Vietnam/1194/2004 clade
1 H5N1 isolate. The BPL-inactivated NIBRG23 H5N1
antigen was used on serums from study 3; the NIBRG23
is a 6/8 PR8-based reverse genetics mutant containing
the HA (Genbank: ABQ58921) and NA of the A/turkey/
Turkey/1/2005 clade 2.2 H5N1 HPAI isolate. The H5N8
A/turkey/Ireland/1378/83 antigen, homologous to the
HA used in the vFP89 vaccine was also used in studies
2, 3 and 4 and the BPL-inactivated A/chicken/West
Java-Subang/29/2007 was used in study 4. The serums of
breeders were also tested with the H5N9 antigen as well as
with the NIBRG14 (studies 1 and 2) or NIBRG23 (studies
3 and 4) H5N1 antigen. The HI tests on serums from
breeder hens were performed at Merial; those from their
progeny of studies 1 to 3 and from study 4 were performed
at Merial and SEPRL, respectively. The first tested serum
dilution was 1 log2 (studies 1 to 3) and 3 log2 (study 4).
The level of viral shedding after challenge was evalu-
ated in study 4 by M-based real time reverse transcript-
ase (RT) PCR on RNA extracted from swabs as
previously described [20].
Statistical analyses were performed using the STAT-
GRAPHICS and SAS/PC softwares. Analysis were car-
ried out by applying the one-way analysis of variance
(1-ANOVA) or two-way analysis of variance (2-ANOVA)
with factors “origin of the birds” and “vaccination scheme”
and pairwise multiple comparison procedure by the
Student’s t-test. Statistical difference was based on two-
tailed tests of the null hypothesis resulting in p-value
of 0.05 or less. A value of 0 (studies 1-3) and 2 log2
(study 4) were set for serums that tested negative for statis-
tical analysis.
Results
Antibody titers in the breeders and progeny
Mean H5N1 and H5N9 HI titers in the breeder hens
before and after egg harvest and in their one-day-oldy (down left) of the HA1 domain of the different H5







/Indonesia/7/2003 [H5N1 clade 2.1.1] (ck/Ind/03 H5N1) is inserted into the
aly/22A/98 [H5N9] (ck/Ita/98 H5N9) is used in the inactivated inH5N9 vaccine.
es from A/Vietnam/1194/2004 [H5N1 clade 1] (Vtn/04 H5N1) and from A/
/West Java-Subang/29/2007 [H5N1 clade 2.1.3.2] (ck/WJ/07 H5N1) was used
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mean HI titers in the progeny were lower (by 1 to 4
log2) than in their parent hens.
Study 1
Assessment of seroconversion was performed at the time
of first (D0) or second (D21) vaccination and after the
second vaccination (day 42 (D42) and 84 (D84)). Mean
HI titers using two different antigens (H5N1 clade 1 and
H5N9) are presented in Figure 1 and the HA1 amino
acid homologies between the vaccine and HI antigens
are shown in Table 2. The vFP2211 at 3 log10 TCID50/
dose induced a low antibody response (2-3 log2) with
both antigens that peaked between D21 and D42 in SPF
chicks without MDA. In birds with FP/H5N9 MDA, the
induced antibody response was decreased by 1-2 log2
suggesting an interference of MDA on vFP2211 im-
munogenicity. This difference was statistically significant
(p = 0.046) with the H5N1 antigen at D21. Increasing the
vFP2211 dose to 5 log10 did not increase the HI titers in
presence of MDA. One administration of the inH5N9
vaccine in birds with MDA induced an antibody re-
sponse of 5 and 3 log2 against homologous H5N9 and
heterologous H5N1 antigens, respectively. When birds
were primed with vFP2211 (dose of 5 log10), the anti-
body titers after the inH5N9 boost were significantly
higher than after the inH5N9 alone. Interestingly, titers
against both H5N1 and H5N9 antigens were similar.
Overall, results of study 1 indicated a slight interference
of FP and/or H5N9 MDA on vFP2211 immunogenicity.
However, vFP2211 priming before inH5N9 administra-
tion significantly increased the HI titers after the boost
indicating an efficient vFP2211 priming despite the pres-
ence of MDA.Table 3 H5N1 and H5N9 HI titers in breeders and their proge
Study Type of breeders
(age at egg harvest)
HI titers* in breede
Age at blood samp
1 H5N9 + FP (42 weeks) 36 weeks
44 weeks
2 H5N9 + FP (62 weeks) 60 weeks
68 weeks
3 H5N9 (24-25 weeks) 20 weeks
28 weeks
H5(N8) + H5N9 + FP (24-25 weeks) 20 weeks
28 weeks
4 H5N9 (58 weeks) 52 weeks
60 weeks
Breeders hens were vaccinated with inH5N9 and fowlpox (H5N9 + FP), inH5N9 only
were taken at two time points flanking the time of harvest of their eggs. Serums of
antigens were used in studies 1 & 2 and studies 3 & 4, respectively.
*mean HI titer ± standard deviation in log2.
**ND means not done.Study 2
Assessment of seroconversion induced by a homologous
(inH5N9 + inH5N9) or a heterologous (vFP89 + inH5N9)
prime-boost scheme was performed at the time of first
(D0) or second (D21) vaccination or after the second
vaccination (D28 and D42) in SPF chickens or chickens
with FP and H5N9 MDAs. Results of the HI test using
three different antigens (H5N1 clade 1, H5N8 and
H5N9) are presented in Figure 2 and the HA1 amino
acid homologies between the vaccine and HI antigens
are shown in Table 2.
After the first inH5N9 vaccine administration at D0,
no clear seroconversion was observed in birds with
MDA at D21. In SPF chicks, the vFP89 induced at D21 a
mean homologous H5N8 HI titer of 4.5 log2. However,
no H5N8 seroconversion was observed with this vaccine
in birds with MDA indicating that FP and/or AI MDA
had negative impact on vFP89 AI immunogenicity.
In presence of anti-FP and anti-H5N9 maternal anti-
bodies, the group vaccinated at both D0 and D21 with
inH5N9 had surprisingly no seroconversion against the
H5N1 and H5N8 antigens and a very low seroconversion
against the H5N9 homologous antigen after the 2nd ad-
ministration suggesting an interference of the MDA
on the inH5N9 immunogenicity. In contrast, the group
receiving the vFP89 priming at D0 followed by inH5N9
at D21 clearly showed a seroconversion in presence of
MDA for the 3 antigens that was significantly higher at
D28 for the H5N8 antigen and at D42 for all 3 antigens
than the groups receiving 2 times inH5N9. However, the
same prime-boost scheme in SPF chicks induced higher
HI titers than in birds with H5N9 + FP MDA. The HI
titers in SPF without MDA were significantly higher
with H5N8 and H5N9 antigens at both D28 and D42ny
rs HI titers in progeny
ling H5N1 H5N9 H5N1 H5N9
4.0 ± 1.8 7.5 ± 2.2 2.0 ± 2.2 3.5 ± 3.0
2.9 ± 2.1 7.5 ± 2.5
3.5 ± 1.9 6.5 ± 2.7 1.0 ± 1.7 3.1 ± 2.7
3.0 ± 1.9 6.6 ± 2.1
4.9 ± 2.0 7.1 ± 1.7 3.0 ± 1.9 4.3 ± 2.0
4.3 ± 2.5 5.9 ± 2.0
ND** 7.0 ± 1.6 1.8 ± 1.1 3.0 ± 1.9
ND 5.3 ± 1.9
3.9 ± 2.7 5.0 ± 2.1 ND 3.4 ± 0.9
4.6 ± 2.2 5.8 ± 2.3
(H5N9) or with vFP89, inH5N9 and fowlpox (H5(N8) + H5N9 + FP). Their serums
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SPF - vFP89 at D0 / inH5N9 at D21
MDA H5N9+FP - vFP89 at D0 / inH5N9 at D21





















































B    H5N8 HI titers
Figure 2 Study 2 Kinetics of HI antibody titers induced by
different vaccines. Mean HI titers (log2) using (A) H5N1 clade 1
(NIBRG14), (B) H5N8 and (C) H5N9 antigens on D0, D21 (3 weeks
after the 1st vaccination), D28 and D42 (1 and 3 weeks after the 2nd
vaccination, respectively). Two groups of chicks with H5N9 and FP
MDA were vaccinated either with vFP89 at D0 followed by inH5N9
at D21 (prime-boost) or inH5N9 at both D0 and D21. The third
group was SPF chicks without MDA vaccinated with the
prime boost.
MDA H5N9+FP - vFP2211 (5log10) at D0 / inH5N9 at D21
MDA H5N9+FP - inH5N9 at D21
MDA H5N9+FP - vFP2211 (3log10) at D0
MDA H5N9+FP - vFP2211 (5log10) at D0


































B    H5N9 HI titers
Figure 1 Study 1 Kinetics of HI antibody titers induced by
different vaccines. Mean HI titers (log2) using (A) H5N1 clade 1
(NIBRG14) and (B) H5N9 antigens in the serum of five groups of
vaccinated chickens. One group of SPF chickens was vaccinated with 3
log10 of vFP2211. The four other groups had H5N9 and FP MDA and
were vaccinated either with 3 or 5 log10 of vFP2211 at D0, with inH5N9
at D21, or with 5 log10 of vFP2211 at D0 followed by inH5N9 at D21
(prime-boost). HI titers were evaluated at D0, D21 (3 weeks after the
vaccination with vFP2211), D42 and D84 (3 and 9 weeks, respectively,
after the 2nd vaccination with inH5N9 in the prime-boost group).
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respectively; H5N9 antigen: p = 0.02 and p = 0.04, re-
spectively) but not with the heterologous H5N1 antigen
(Kruskal-Wallis test: p = 0.71 and 0.69, respectively).
Note that the identity and similarity between the HA1
amino acid sequence of the vaccines and the H5N1 clade
1 (NIBRG14) HI antigen was lower or equal to 90% and
95%, respectively (Table 2).
Study 3
Chickens with or without MDA (SPF) were used in this
3rd study. Chicks with MDA had either (1) H5N9 MDA,
(2) FP MDA or (3) H5(N8) + H5N9 + FP MDA (see Ma-
terials and methods). They were vaccinated with vFP89
at D0 and inH5N9 at D14 or with inH5N9 only (see
Table 1). Assessment of seroconversion in the vaccinated
birds was performed at D0, D14, D28 and D42. HI test
was performed with three different antigens (H5N1clade 2.2, H5N8 and H5N9). The HA1 amino acid hom-
ologies between the vaccines and the H5N1 clade 2.2
(NIBRG23) HI antigen were similar than between the
vaccines and the H5N1 clade 1 (NIBRG14) antigen used
in studies 1 and 2 (Table 2).
The HI titre kinetics in SPF, H5N9 MDA or H5(N8) +
H5N9 + FP MDA birds vaccinated only once with
inH5N9 at D14 is shown in Figure 3. A clear interfer-
ence of AI MDA was observed on the immunogenicity
of inH5N9 vaccine and this interference was higher in



















SPF - inH5N9 at D14
MDA H5N9 - vFP89 at D0 / inH5N9 at D14
MDA H5N9 - inH5N9 at D14
Figure 4 Study 3 Overcoming MDA-interference on inH5N9
vaccine by vFP89 priming. Mean HI titers (log2) using H5N1
(NIBRG23), H5N8 and H5N9 antigens on D28 and D42 (2 and
4 weeks after the inH5N9 vaccination). Birds were either SPF
without MDA or had H5N9 MDA and were vaccinated with vFP89
at D0 and inH5N9 at D14 (birds with MDA) or inH5N9 at D14 only
(birds with or without MDA).
D0 D14 D28 D42
SPF - inH5N9 at D14
MDA H5N9 - inH5N9 at D14




























































C    H5N9 HI titers
Figure 3 Study 3 Kinetics of HI antibody titers induced by the
inH5N9 vaccine. Mean HI titers (log2) using (A) H5N1 (NIBRG23),
(B) H5N8 and (C) H5N9 antigens on D0, D14, D28 and D42 in
groups vaccinated with inH5N9 at D14. The birds of these three
groups were SPF (no MDA) or with H5N9 MDA or with
H5(N8) + H5N9 + FP MDA.
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those obtained in SPF birds. Indeed, HI titres in H5N9
MDA chicks at D42 were significantly lower (t-test:p = 0.022 and p < 0.001 for H5N1 and H5N9 antigens,
respectively) than those obtained in H5(N8) +H5N9 + FP
MDA chicks; at D28, a lower HI titer in H5N9 MDA ver-
sus H5(N8) +H5N9 + FP MDA birds was also observed for
both H5N8 and H5N9 antigens but the difference was sig-
nificant (p = 0.003) with the H5N9 antigen only. These
results suggest that the level of MDA interference on
inH5N9 immunogenicity depends on the number of
inH5N9 administrations given to the breeders. In chicks
with H5N9 MDA, the vFP89 priming at D0 could clearly
overcome the interference of H5N9 MDA on inH5N9 vac-
cine D14 immunogenicity, since on both D28 and D42
and for the 3 antigens, the HI titres were significantly
higher than those induced after one inH5N9 administra-
tion to H5N9 MDA chicks (t-test: p = 0.02, p = 0.002 and
p = 0.003 at D28, and p = 0.01, p = 0.0001 and p = 0.017 at
D42 for H5N1, H5N8 and H5N9 antigens, respectively)
and not different (p > 0.05) from those induced after one
inH5N9 administration to SPF chicks (see Figure 4).
HI titer kinetics of birds with or without MDA vacci-
nated with the prime-boost scheme are shown in Figure 5.
The highest antibody response against the 3 antigens
was observed in SPF chicks without MDA. A clear
MDA interference was observed mainly on D28 in
chicks with H5(N8) + H5N9 + FP MDA, for which the
D0 D14 D28 D42
SPF - vFP89 at D0 / inH5N9 at D14
MDA H5N9 - vFP89 at D0 / inH5N9 at D14
MDA H5(N8)+H5N9+FP - vFP89 at D0 / inH5N9 at D14































































C    H5N9 HI titers
Figure 5 Study 3 Kinetics of HI antibody titers induced by the
prime-boost. Mean HI titers (log2) using H5N1 (A), H5N8 (B) and
H5N9 (C) antigens on D0, D14, D28 and D42 in groups vaccinated
with the prime-boost (vFP89 at D0 and inH5N9 at D14). The birds of
these four groups were SPF or with H5N9 MDA or with FP MDA or
with H5(N8) + H5N9 + FP MDA.
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with other types of MDA (see Figure 5). This interference
was less pronounced on D42. The statistical analysis con-
firmed this difference on D28, HI titres from chicks with
H5(N8) + H5N9 + FP MDA being significantly lower
than those in SPF chicks for the three antigens (t-test:
p = 0.006, p = 0.002 and p = 0.004 for H5N1, H5N8 and
H5N9 antigens, respectively), lower than those in
chicks with H5N9 MDA with the H5N8 antigen only
(t-test: p = 0.028) and lower than those in chicks with
FP MDA with the H5N1 and H5N8 antigens (t-test:
p = 0.024 and p = 0.008, respectively).In chicks with FP MDA, vFP89-induced H5N8 HI ti-
tres at D14 were only slightly (non-significant difference
of about 0.6 log2) lower than those obtained in SPF
chicks (see Figure 5B). In contrast, these H5N8 HI titres
induced by vFP89 at D14 were significantly lower (about
3 log2) in chicks with H5N9 or H5(N8) + H5N9 + FP
MDA compared to SPF and FP-MDA birds. These data
indicate that the anti-HA insert AI MDA had more in-
hibitory effect on vFP89-induced H5N8 HI titers than
the anti-vector FP MDA. After the inH5N9 boost, HI ti-
tres were slightly lower than in SPF (1-2 log2 difference
significantly different at D42 and for H5N9 antigen only)
suggesting a slight interference of the FP MDA on the
vFP89 priming efficiency. In chicks with H5N9 MDA, the
HI titers induced by the prime-boost regimen were lower
than in SPF but the difference was statistically significant
(p = 0.021) at D28 and for the H5N9 antigen only.
Study 4
Eight groups of chicks with FP, with H5N9 or without
(SPF) MDA were used in this 4th study (see Materials
and methods and the design in Table 1). Results of ser-
ology with H5N8 and H5N9 antigens, clinical protection
and shedding after challenge are summarized in Table 4.
Results of serology with the A/chicken/West Java-
Subang/29/2007 [H5N1 clade 2.1.3.2] challenge strain
antigen are not shown since all serums were negative
(titer < 3 log2) before challenge (D28). The HA1 amino
acid homology of the vaccines with theH5N1 clade
2.1.3.2 challenge strain was indeed lower than with the
H5N1 clade 1 or 2.2 antigens (Table 2). Furthermore,
the HA1 amino acid sequence of this challenge strain
had mutations at critical positions adjacent to the recep-
tor binding site: in particular, it had the S133A and
A185E mutations responsible for the antigenic drift of
the A/chicken/West Java/30/2007 isolate, and one
(I151T) of the 4 significant changes responsible for the
antigenic drift of the A/chicken/West Java/119/2010 iso-
late [16]. The number of positive birds (HI titer ≥ 3log2)
and the mean HI titer ± standard deviation in 5 birds
with H5N9 MDA sacrificed at 1 day of age were 5/5 at
4.2 ± 1.1 log2 and 4/5 at 3.4 ± 0.9 log2 with the H5N8
and the H5N9 antigens, respectively. After challenge with
the Indonesian H5N1 antigenic variant HPAI, all 10 SPF
and all 9 MDA H5N9 unvaccinated control birds died
2 days post-challenge (dpc) (mean death time (MDT) of
2.0) confirming the severity of the challenge and the ab-
sence of H5N9 MDA protection at 28 days of age. At 2
dpc, high levels of oropharyngeal viral excretion were
detected for all unvaccinated control birds (7.8 and 7.3
log10 EID50-equivalents in chicks without or with H5N9
MDA, respectively).
The vFP89 alone induced homologous H5N8 HI titers
at D14 (3.7 log2 mean HI titer) and D28 (5.5log2) in all
Table 4 Results of the vaccination-challenge study (Study 4)
Group MDA Vaccine H5N8 HI titersa H5N9 HI titers Protectionb Oropharyngeal sheddingc
D0 D14 D14 D28 D28 (MDT) 2 Dpc 4 Dpc
1 - - - NDd 0/10 (2.0 ± 0.0) 0/10 (2.0 ± 0.0) 0/10 (2.0) 10/10 (7.8 ± 0.3) ND
2 - vFP89 - 10/10 (3.7 ± 0.8) 10/10 (5.5 ± 1.2) 8/10 (2.9 ± 0.6) 1/10 (3.4) 10/10 (6.3 ± 1.3) 5/5 (6.6 ± 0.7)
3 FP vFP89 inH5N9 2/9 (2.3 ± 0.7) 9/9 (8.1 ± 1.6) 9/9 (7.6 ± 1.8) 9/9 6/9 (4.6 ± 0.7) 4/9 (4.0 ± 0.5)
4 FP - inH5N9 ND 9/9 (5.1 ± 1.6) 9/9 (5.8 ± 0.7) 5/9 (7.3) 7/9 (4.9 ± 0.9) 4/9 (4.6 ± 1.0)
5 H5N9 - - ND 0/9 (2.0 ± 0.0) 0/9 (2.0 ± 0.0) 0/9 (2.0) 9/9 (7.3 ± 0.1) ND
6 H5N9 vFP89 - ND 5/9 (2.9 ± 0.9) 0/9 (2.0 ± 0.0) 0/9 (2.7) 9/9 (7.1 ± 0.5) 1/1 (7.7)
7 H5N9 vFP89 inH5N9 0/9 (2.0 ± 0.0) 9/9 (5.8 ± 1.0) 9/9 (4.3 ± 1.1) 7/9 (7.0) 6/9 (4.5 ± 0.6) 7/9 (4.6 ± 1.3)
8 H5N9 - inH5N9 0/9 (2.0 ± 0.0) 4/9 (3.2 ± 1.6) 6/9 (3.7 ± 1.7) 4/9 (5.0) 8/9 (5.0 ± 1.0) 7/8 (5.3 ± 1.1)
Results of serology, protection and oropharyngeal viral shedding in chicks with or without FP or H5N9 MDA vaccinated or not with vFP89 and/or inH5N9 and
challenged at D28 with an HPAI H5N1 Indonesian isolate (A/chicken/West Java-Subang/29/2007).
aNumber of positive birds (HI titer ≥ 3 log2)/total; the mean HI titer ± standard deviation is given between brackets.
bNumber of birds protected against mortality/total; the mean death time (MDT) is given between brackets.
cNumber of positive birds (≥3.8 log10 EID50-equivalent)/total; the mean viral RNA load ± standard deviation is given in log10 EID50-equivalent between brackets;
Dpc, day post-challenge.
dND means not done.
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H5N8 seroconversion after vFP89 vaccination was ob-
served in none (0/9) of the birds at D14 (group 7) and in
only 5/9 birds (2.9 log2) at D28 (group 6) indicating an
interference of H5N9 MDA on vFP89 immunogenicity.
In birds with FP MDA, 2/9 birds had detectable H5N8
antibodies (2.3 log2) 14 days after vFP89 vaccination.
This decrease of vFP89 immunogenicity in FP MDA
birds compared to SPF birds was higher than in study 3
(1.4 log2 and 0.6 log2 decrease in study 4 and 3, re-
spectively). Only one out of ten SPF birds without
MDA was clinically protected after the vFP89 vaccine
alone (MDT 3.4), whereas none of the 9 vFP89-
vaccinated birds with H5N9 MDA survived after chal-
lenge (MDT 2.7); this difference was not significant.
Viral shedding was detected in all vFP89-vaccinated
challenged birds at similar levels as non-vaccinated
control (7.1 and 7.7 log10 at 2 and 4 dpc, respectively)
in birds with H5N9 MDA (group 6) and at slightly
lower levels (6.3 and 6.6 log10 at 2 and 4 dpc, respect-
ively) in SPF birds (group 2). These results indicated a
low level of protection induced by vFP89 alone against
this variant Indonesian HPAI H5N1 isolate which may
further be decreased by the presence of AI MDA.
The inH5N9 alone induced higher homologous H5N9
HI titers and in a higher proportion of birds (mean titer
of 5.8 log2; 9 positive/9 birds) at D28 in FP (group 4)
compared to H5N9 MDA (group 8) chickens (mean titer
of 3.7 log2; 6 positive/9 birds) confirming the negative
impact of H5N9 MDA on the inH5N9 immunogenicity.
After challenge, 5/9 or 4/9 chickens with FP (group 4)
or H5N9 MDA (group 8), respectively, were clinically
protected. The mean death time was higher in group 4
(7.3) than in group 8 (5.0). There was no relationbetween D28 HI titers and clinical protection for group
4 (inH5N9 at D14 in FP MDA) since dead birds
pre-challenge H5N8 and H5N9 HI titers (4-6 and 6
log2, respectively) were similar than those in protected
birds (4-9 and 5-7 log2, respectively). Interestingly, such
relation existed for group 8 (inH5N9 at D14 in H5N9
MDA): all 5 dead birds were negative (<3 log2) with
H5N8 antigen, and negative (3 birds) or at minimum
titer (3 log2 in 2 birds) with homologous H5N9 antigen
whereas all protected birds had detectable D28 H5N8
and H5N9 HI titers ranging from 4 to 6 log2. The viral
shedding at 2 dpc of groups 4 and 8 was comparable
(about 5 log10 in all but 1 or 2 birds) and 2.9 or 2.3
log10 lower than the unvaccinated controls in FP or
H5N9 MDA chickens, respectively. The shedding at 4
dpc was slightly lower in group 4 (mean titer of 4.6
log10 detectable in 4/9 birds) than in group 8 (mean
titer of 5.3 log10 detectable in 7/8 birds). No relation
was found between D28 HI titers and the level of shedding.
These results indicate that this experimental inH5N9 vac-
cine was only partially protective against this Indonesian
HPAI H5N1 challenge and that H5N9 MDA decreased its
immunogenicity.
The groups that received the heterologous prime-
boost regimen in presence of FP (group 3) or H5N9
(group 7) MDA induced higher HI titers (7.6 vs 5.8 in
FP MDA birds and 4.3 vs 3.7 log2 in H5N9 MDA birds)
and/or in a higher number of birds (9/9 vs 6/9 in H5N9
MDA birds) than birds that received the inH5N9 only
(groups 4 and 8). These birds of group 3 and 7 were also
better clinically protected (9/9 and 7/9 (MDT 7.0), re-
spectively) than those of groups 4 and 8 (5/9 (MDT 7.3)
and 4/9 (MDT 5.0), respectively). The levels of viral
shedding of groups 3 and 7 were comparable to those
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tion between HI titers at D42 and clinical protection
or shedding level in birds from groups 3 and 7. The
prime-boost regimen improved the immunogenicity and
protection levels compared to one inH5N9 administration
for all tested condition (anti-vector FP MDA and anti-
H5N9 MDA).
Discussion
Most published studies on the efficacy of avian influenza
vaccines in chickens are performed in SPF chickens
without MDA. In endemic countries in which vaccin-
ation is practiced, breeder flocks are heavily vaccinated
due to their very high economic value in both egg and
poultry meat productions. Consequently, breeder hens
transfer high MDA levels to their progeny which may
protect the hatched chicks but may also interfere with
vaccine efficacy. Therefore, the level of immunogenicity
and protection induced by vaccination in the presence of
MDA is important to evaluate. The study of MDA inter-
ference is complex since many factors can influence the
data including (1) the vaccination protocol and the types
of vaccines used in the breeders, (2) the time between
immunization of breeder hens and collection of their
eggs, (3) the type of birds and in particular their growth
rate which influences the kinetics of MDA decrease after
hatching, (4) the heterogeneity of MDA levels in the
progeny, (5) the age of vaccination and the type of vac-
cine used in the progeny, and (6) the timing of challenge
with a possible protective effect of MDA. Using vector
vaccines, both MDA against the vector and against the
targeted disease agent need to be evaluated since both
may potentially interfere with immunogenicity. Our ob-
jective was to evaluate the MDA interference on FP-
vectored and inactivated H5 vaccines’ immunogenicity
and protection. Different vaccination schemes were
tested and compared in SPF chicks and chicks with
MDA.
Mean HI titers in 1-day-old chicks were lower (by 1 to
4 log2) than those in their parent hens. A similar differ-
ence (2.1-2.5 log2) in homologous H5N2 HI titers be-
tween the serum of vaccinated broiler breeder hens and
their progeny was previously reported [21,22]. The dif-
ference is probably due to a low level (about 10%) of em-
bryo IgY absorption from the egg yolk [23]. The low
titer in 1-day-old chick may also be due to the incom-
plete resorption of the yolk sac in the newly hatched
chicks. Antibody continues to be absorbed from the yolk
sac after hatching [24] and total serum IgY levels were
shown to increase to their maximum value at about
2 days post-hatch [25]. We have observed similar and
even higher mean HI titers (up to 1.7 log2 higher) be-
tween day of hatch and one week-of-age in SPF white
Leghorn type of birds hatched from vaccinated hens(Bublot et al., unpublished results). The small number of
birds used to evaluate the mean HI titers in hens and
one-day-old chicks may also explain the variable differ-
ence between these hen and progeny titers in different
studies. Measuring the antibody titer after a couple days
of live and in a higher number of animals could give a
more accurate level of MDA.
Results of study 1 indicated that FP and/or H5N9
MDA can slightly interfere with vFP2211 immunogen-
icity. In addition, increasing the dose of vFP2211 by 2
log10 did not induce an increase in HI titers. The im-
munogenicity of the inH5N9 alone in birds with FP and
H5N9 MDA was lower than expected in both studies 1
and 2 but there was no control group of SPF birds re-
ceiving the inH5N9 alone to show that this lower im-
munogenicity was due to MDA interference. However,
vFP2211 priming before inH5N9 administration signifi-
cantly increased the HI titers after the boost in study 1
indicating an efficient vFP2211 priming despite the pres-
ence of FP and H5N9 MDA. Interestingly, the HI titers
against both H5N9 and H5N1 antigens were similar
after the prime-boost. In study 2, the heterologous
prime-boost vaccination regimen using the vFP89 +
inH5N9 combination clearly induced a higher HI anti-
body response than the homologous inH5N9 + inH5N9
prime-boost in birds with MDA confirming the superior
immunogenicity of the heterologous prime-boost com-
pared to two administrations of inH5N9 vaccine in birds
with MDA. However, the immune response induced by
the heterologous vFP89 + inH5N9 prime-boost in birds
with FP and H5N9 MDA was lower than in SPF birds
indicating that MDA interfered on this vaccination
scheme.
In the first two studies, chicks with both AI and FP
MDA were used and therefore it was not possible to de-
termine if the interference observed was due to the anti-
vector and/or to the anti-AI maternal immunity. In
addition, the MDA interference on the inH5N9 im-
munogenicity was not assessed. Studies 3 and 4 were
therefore designed to answer to these questions in terms
of immunogenicity (both studies 3 and 4) and efficacy
(study 4). In study 3, the highest MDA interference (3-4
log2 lower than in SPF at D28 and D42) was observed
on the immunogenicity of the inH5N9 vaccine given at
14 day-of age to birds hatched from breeders vaccinated
three times with the same inH5N9 vaccine. Interestingly,
in birds hatched from breeders vaccinated with a prime-
boost regimen including only one administration of
inH5N9, the interference was lower (see Figure 3), indi-
cating that the number of vaccination applied to the
breeders may influence the immunogenicity of the same
vaccine given to the progeny. These results supported
the hypothesis that the poor immunogenicity of the
inH5N9 vaccine observed in studies 1 and 2 was due to
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interference of inH5N9 MDA on the inH5N9 immuno-
genicity was observed in study 4 (groups 4 and 8 in
Table 4); this lower interference was probably due to the
lower H5N9 MDA titers in chicks from study 4 (Table 3)
because the timing of harvest of eggs from breeders was
much later in study 4 (58-week-old breeders) than in
study 3 (24-week-old breeders). The H5N1 HPAI protec-
tion induced by one-shot (D14) of inH5N9 vaccine in
birds with or without H5N9 MDA was not significantly
different in the tested conditions of study 4. However,
birds with H5N9 MDA (group 8) tended to be less pro-
tected than those without H5N9 MDA (group 4): (1)
one additional bird died (5/9 vs 4/9), (2) mean time to
death was 2.3 days shorter (5.0 vs 7.3) and (3) the num-
ber of birds shedding the virus at 2 and 4 dpc was higher
(total of 15/17 vs 11/18) (Table 4). Interestingly, there
was a clear relation between H5N8 and H5N9 HI titers
at D28 and clinical protection in birds with H5N9
MDA (all birds with a H5N8 and H5N9 titer ≥ 4 log2
were protected and those with a titer ≤ 3 log2 died) but
not in birds with FP MDA (dead birds had similar
H5N8 and H5N9 titers (4-6 log2) than protected ones
(4-9 log2)). Prediction of protection based on H5N9
and H5N8 HI titers before this Indonesian antigenic
variant challenge was therefore valid in birds with but
not in birds without H5N9 MDA. At similar inH5N9-
induced H5N9 and H5N8 HI titers (4-6 log2) before
challenge, all 4 birds hatched with H5N9 MDA were
protected whereas only 4/8 birds with no AI MDA
resisted the challenge. Additional studies need to be
performed to confirm these results and to identify the
immune response differences that lead to the same HI
titers but a different level of protection in birds with or
without AI MDA.
Passive antibody interference on AI inactivated vac-
cines immunogenicity and efficacy has been reported by
different teams. The MDA impact on inactivated vaccine
immunogenicity was a drop in HI titers ranging from 2
log2 [11] to up to 8 log2 [10]. Protection levels were
however only slightly reduced in birds with MDA after
H5N1 HPAI challenge [11]. Abdelwhab et al. [22]
showed that the MDA interference on immunogenicity
was higher when the same vaccine was used in the
breeders and in the progeny, and when the breeder vac-
cine antigen was used in the HI test. Our data showing
that the MDA interference level was dependent on the
breeder vaccination program are in line with these find-
ings. The MDA interference on inactivated vaccine im-
munogenicity was also strongly suspected in Indonesian
broilers when the same vaccine was used in breeders
and their progeny [26]. Kim et al. [9] and Forrest et al.
[27] simulated the presence of MDA by passive transfer
of hyperimmune serum in young chicks and showed thatsuch transfer also interfered on the immunogenicity and
efficacy of commercial inactivated vaccines. Altogether,
these data confirm that MDA transferred from the vacci-
nated breeders to their progeny interfere with the im-
munogenicity and efficacy of inactivated vaccine given at
least in the first 2 weeks of age, especially when multiple
administrations of the vaccine are used in breeders and
the same vaccine is used in the progeny. The interfer-
ence is detected even with low MDA titers and is lower
when heterologous inactivated vaccines are used in the
progeny. It is therefore important to take into account
this interference when designing the vaccination pro-
gram of breeders and their progeny.
The anti-FP and anti-AI MDA interference on vFP89
immunogenicity could be evaluated only before the
boost (D14) in studies 3 and 4. Anti-FP MDA had only a
slight negative effect on vFP89-induced H5N8 HI titers
in study 3, but in study 4, the negative effect of anti-FP
MDA was higher. After the inH5N9 boost in vFP89-
primed birds with FP MDA in study 3, the HI titers
did not reach the levels obtained after prime-boost
immunization of SPF birds (Figure 5). These results sug-
gest that the vFP89 priming efficiency may have been
partially inhibited by the FP MDA. The priming effect of
vFP89 on inH5N9-induced immunogenicity and protec-
tion (study 4; see Table 4) in birds with FP MDA was ob-
vious since the mean HI titer at D28 and the number of
protected birds were higher with vFP89 priming (group
3) than in the group without vFP89 priming (group 4).
In previous studies performed with vFP89 [7] and with
another FP recombinant expressing Newcastle disease
virus (NDV) protective genes [28], no interference of FP
MDA could be observed on AI and ND protection.
Altogether, these data indicate that there may be a slight
negative interference of anti-FP MDA on the immuno-
genicity of FP vectors but the anti-vector MDA effect on
protection seems minor. This low interference of passive
anti-FP immunity contrasts with the strong one observed
in birds with active FP immunity. Both Swayne et al. [29]
and Iritani et al. [30] have shown in an AI and a NDV
model, respectively, that FP vaccination performed before
administration of the FP recombinants severely decreased
the induced protection. The low interference of passive FP
immunity could be due to the poor level of FP-induced
neutralizing antibodies [31], and the high interference of
active FP immunity to the high FP-induced cellular im-
munity [32].
The interference of anti-AI MDA on vFP89-
immunogenicity in both study 3 and study 4 was more
obvious than that of anti-FP MDA. A lower number of
seropositive birds and a lower mean HI titer (by approxi-
mately 2.5 log2) were detected compared to SPF. These
data suggest that interference of MDA directed against
both FP and AI observed in studies 1 and 2 on vFP2211
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MDA than to anti-FP MDA, without excluding the impact
of anti-FP MDA. No conclusion can be drawn on the ef-
fect of H5N9 MDA on vFP89 efficacy since in the condi-
tions tested in study 4, the vFP89 alone protected only 1/
10 SPF birds and 0/9 birds with H5N9 MDA. The poor
performance of vFP89 in SPF birds against this Indonesian
H5N1 HPAI was surprising since several efficacy studies
([14,15,31], M. Bublot, D.E. Swayne and T. van den Berg,
unpublished data) performed previously in SPF chickens
with other H5N1 HPAI (clade 0, 1, 2.2 and 2.5) showed ef-
ficacy levels ranging from 75-100%. The low vFP89 efficacy
level in SPF observed here is likely due to the antigenic
drift of this Indonesian isolate that contains critical muta-
tions adjacent to the receptor binding site of its HA1 that
were shown to be responsible for antigenic drift in
Indonesia [16]. A similar poor level of protection in-
duced by inactivated vaccines containing seed strains
A/turkey/Wisconsin/1968 (H5N9), A/chicken/Mexico/
28159-232/1994 (H5N2), A/turkey/England/N28/1973
(H5N2), A/chicken/Legok/2003 (H5N1), reverse genetic
A/goose/Guangdong/1/96 (H5N1), or reverse genetic
A/chicken/Vietnam/C57/2004 (H5N3) against another
Indonesian antigenic variant (A/chicken/West Java/PWT-
WIJ/2006 (H5N1 clade 2.1.3)) has been observed (D.E.
Swayne et al., manuscript in review). In previous studies
performed with vFP89 in broilers with both AI and FP
MDA, there was no significant interference of the MDA
on the protection induced against a HPAI H5N2 Mexican
challenge model [7]. However, Faulkner et al. [12] showed
recently the interference of passively transferred anti-
bodies on the immunogenicity and H5N1 HPAI protec-
tion induced by fowlpox- or NDV-vectored AI vaccines
indicating that the level of interference likely depends
on the tested conditions. A slight interference of MDA
directed against the foreign gene product expressed by
the vector vaccine has also been reported for FP-NDV
(vFP-ND) by Taylor et al. [28].
As in studies 1 and 2, the heterologous prime-boost
regimen induced higher HI titers in chicks with AI
MDA than the inactivated vaccine alone. The vFP89
priming was efficient in birds with H5N9 MDA and
override the negative effects of MDA on inH5N9 im-
munogenicity (Figure 4). In study 4, the protection of
the prime-boost in H5N9 MDA was higher (7/9 pro-
tected; MDT 7.0) than that of inH5N9 in FP MDA (5/9
protected; MDT 7.3) or in H5N9 MDA (4/9 protected;
MDT 5.0) confirming the positive effect of the vFP89
priming in both type of birds. Such priming effect of
vectored vaccines has also been observed in a passive
antibody transfer study mimicking MDA [12].
Among the different types of MDA tested (FP, H5N9
or H5(N8) + H5N9 + FP), the highest interference on the
prime-boost immunogenicity (Figure 5) was observed atD28 in birds hatched from breeders vaccinated with the
prime-boost regimen (H5(N8) + H5N9 + FP MDA) sug-
gesting that, as for inactivated vaccine, interference is
higher when the same vaccines and vaccination schemes
are used in breeders and their progeny. Several mecha-
nisms responsible for MDA interference have been pro-
posed including (1) antigen removal by elimination of
immune complexes, (2) neutralization of live vaccine virus,
(3) epitope masking and (4) inhibiting of B-cells by cross-
linking of B-cell receptor, antigen, maternal antibodies and
the Fcγ receptor IIB. Kim et al. [33] found that it was the
latter mechanism which was mainly responsible for inter-
ference in a measles vaccination model in cotton rats. Fur-
ther studies are needed to better understand the
mechanisms of MDA interference in chickens.
The data presented here and recent published work
show that AI MDA can potentially interfere on both
inactivated whole avian influenza virus and live fowl
poxvirus vectored vaccines. Interestingly, the heterol-
ogous prime-boost gave the best immune response and
the best level of protection. Similar fowlpox vector/inacti-
vated vaccine prime-boost was shown to be highly im-
munogenic in ducks [34]. There are at least 3 explanations
for the highest performance of such heterologous prime-
boost [6,35]. Firstly, the two types of vaccine induce differ-
ent type of immunity: the live fowlpox vector vaccine
induces mainly cellular immunity and the inactivated vac-
cine induced mainly humoral immunity, the combination
of two providing a more balanced Th1/Th2 and a broader
immune response. Secondly, the fowlpox vector is express-
ing only HA, the primary protective antigen of influenza
virus. After the boost with the whole virus inactivated vac-
cine, the higher secondary immune response will be di-
rected against the protective HA antigen only and a lower
primary immune response will be induced against the
other antigens. The broader immunogenicity of a prime-
boost regimen using a vector expressing the protective
antigen and protein (or another vector) has been shown
for different antigens [36] including recently for influenza
in mice, ferrets and monkeys [37]. Thirdly, the HA
inserted in the fowlpox vector (from an H5N8 isolate) is
different from the HA present in the inactivated vaccine
(from an H5N9 isolate). The secondary immune response
after the inactivated vaccine boost will be directed
against the epitopes common to the two HA antigens.
These common epitopes (including epitopes from the
HA stem) are thought to be more conserved than the
strain specific epitopes resulting in a broader immune
response [35]. Heterologous prime-boost regimens with
vaccines containing different H5N1 antigens have been
shown to provide broader immunity than homologous
prime-boost ones with the same vaccine [38-40]. Such
successive immunization with HA of different origins
has also recently allowed to generate broadly reactive
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broadly reactive antibodies recognizing the HA stalk
[42]. Similar benefits of a prime-boost vaccination regi-
men in birds with MDA were recently shown in an
HPAI H5N1 model with a herpesvirus of turkey vector
priming [43].
Countries such as Indonesia and Egypt in which H5N1
HPAI infection became endemic have not eradicated the
infection by vaccination. This failure has many explana-
tions [44,45], including the suboptimal use of vaccines that
seems to have led to the emergence of new antigenic vari-
ants against which the classical vaccines are not fully pro-
tective [3,16,46]. MDA interference on vaccine efficacy
likely contributes also to the lack of control by vaccination
[9,26]. Results presented here confirm the high MDA
interference on inactivated vaccines and suggest that the
use of a prime-boost strategy using a fowlpox vector to
prime may be able to overcome at least partially MDA
interference. Furthermore, the vaccines and vaccination
protocol used in breeders and in their progeny need to be
different to minimize MDA interference. Additional vac-
cination/challenge studies need to be done in field condi-
tions to find the optimal vaccination schemes providing
the best protection in breeders and in their progeny.
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